Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

4.60
-0.2600-5.35%
Post-market: 4.50-0.1000-2.17%19:57 EDT
Volume:2.01M
Turnover:9.20M
Market Cap:524.40M
PE:-3.29
High:4.92
Open:4.80
Low:4.37
Close:4.86
52wk High:6.16
52wk Low:1.60
Shares:114.00M
Float Shares:102.00M
Volume Ratio:1.53
T/O Rate:1.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3971
EPS(LYR):-1.2306
ROE:-41.65%
ROA:-23.35%
PB:2.53
PE(LYR):-3.74

Loading ...

Perspective Therapeutics Reports Positive Interim Results for [212Pb]VMT-α-NET in Neuroendocrine Tumor Trial

Reuters
·
Jan 09

Perspective Therapeutics Presents Updated Interim Data of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial at the 2026 Asco Gastrointestinal Cancers Symposium

THOMSON REUTERS
·
Jan 09

Perspective Therapeutics Reports Promising [212Pb]VMT-α-NET Data in Neuroendocrine Tumor Trial

Reuters
·
Dec 04, 2025

Perspective Therapeutics (CATX) Receives a Buy from Roth MKM

TIPRANKS
·
Nov 28, 2025

Perspective Therapeutics (CATX) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 26, 2025

Perspective Therapeutics Inc : Truist Securities Assumes Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
Nov 24, 2025

Perspective Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Nov 22, 2025

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program

TIPRANKS
·
Nov 21, 2025

Perspective Therapeutics price target lowered to $7 from $18 at UBS

TIPRANKS
·
Nov 21, 2025

Perspective Therapeutics to Participate in Upcoming December Conferences

GlobeNewswire
·
Nov 20, 2025

Perspective Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Nov 19, 2025

B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating

MT Newswires Live
·
Nov 18, 2025

Perspective Therapeutics Chief Accounting Officer Jonathan Robert Hunt Acquires Common Shares

Reuters
·
Nov 17, 2025

Director Robert F. Williamson III Acquires Common Shares of Perspective Therapeutics Inc

Reuters
·
Nov 14, 2025

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 12, 2025

Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability

TIPRANKS
·
Nov 12, 2025

Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential

TIPRANKS
·
Nov 12, 2025

Wedbush Keeps Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 11, 2025

Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer

TIPRANKS
·
Nov 11, 2025

BTIG Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 11, 2025